REUTERS/Brendan McDermidLONDON, Sept 20 (Reuters) - Haleon (HLN.L) on Tuesday said it had notified GSK (GSK.L) and Pfizer (PFE.N) that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.
More than 2,000 legal cases related to Zantac have been filed in the United States over allegations that the compound contains a probable carcinogen.
Zantac, originally marketed by a forerunner of GSK, has been sold by several companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi (SASY.PA) as well as a plethora of generic drugmakers.
Haleon - alongside GSK, Sanofi and Pfizer - saw billions wiped off their market value last month as uncertainty around the outcome of the impending litigation triggered investor concern, although some of those losses have been since pared back.
However, in August, Haleon clarified that it never marketed Zantac in any form in the U.S., either as Haleon or as GSK consumer healthcare.